

SECTION 1: IDENTIFICATION	
1.1 Product identifier	
Product name:	Prednidale® (5mg and 25mg tablets)
Synonyms:	Not Available
Proper Shipping name:	Not Available
Other means of identification:	None
1.2 Relevant identified uses of the substances or mixture and uses advised against	
Recommended uses:	For the treatment of inflammatory and allergic diseases, including some autoimmune diseases and some neoplastic conditions in cats and dogs. Inflammatory, allergic and autoimmune processes may be involved in cutaneous, alimentary, respiratory, musculo-skeletal and haematological manifestations of disease.
Uses advised against:	Not for human use. Do not use in animals with renal insufficiency, diabetes mellitus or corneal ulceration. Do not use in animals receiving vaccines containing live organisms. Do not use in pregnant animals.
1.3 Details of the supplier of the substance or mixture	
Registered company name:	Dechra Ltd
Address:	Snaygill Industrial Estate Keighley Road Skipton North Yorkshire BD23 2RW UK
Telephone:	+44 (0) 1756 791311
Fax:	+44 (0) 1756 798604
Email:	Not available
1.4 Emergency Telephone Numbers	
	+44 (0) 1756 791311

SECTION 2: HAZARDS IDENTIFICATION	
2.1 Classification of the substance or mixture	
DSD Classification (EU):	Not Available
DPD Classification (EU)¹:	Not Available
Classification according to regulation (EC) No 1272/2008 [CLP] (EU)¹:	Not Available
2.2 Label Elements	
Signal Word:	NOT AVAILABLE
Hazard Statement(s)	
Not available	
Precautionary Statement(s) Prevention:	
Not available	
Precautionary Statement(s) Response:	
Not available	
Precautionary Statement(s) Storage:	
Not available	
Precautionary Statement(s) Disposal:	
Not available	
2.3 Other Hazard Information	
Not available	

SECTION 3: INFORMATION ON THE INGREDIENTS	
3.1 Substances	
See section below for composition of mixtures	

3.2 Mixtures			
1.CAS No 2.EC Number 3.Index Number 4.REACH Number	% w/v	Name	Classification according to regulations (EC) No 1272/2008 [CLP] (EU)
1. 50-24-8 2. 200-021-7 3. Not Available	0.5 - 2	Prednisolone	Acute toxicity (oral) category 4, H302 ¹

4. 01-2119560581-40-XXXX			
N/a	Proprietary	Other ingredients determined not to be hazardous	N/a
Legend: 1. Classified by Chemwatch			

SECTION 4: FIRST AID MEASURES	
4.1 Description of first aid measures	
Eye contact:	In case of accidental contact of the product with the eyes rinse abundantly with fresh water. Seek medical attention if irritation occurs, showing the package leaflet or the label to the medical practitioner.
Skin contact:	In case of accidental contact of the product with the skin, rinse with fresh water. Seek medical attention if irritation occurs, showing the package leaflet or the label to the medical practitioner.
Inhalation:	If difficulty in breathing develops or persists, seek medical attention.
Ingestion:	Following accidental ingestion, rinse out mouth and drink bland fluids; do not induce vomiting. In the event of
4.2 Most important symptoms and effects, both acute and delayed	
See Section 11	
4.3 Indication of immediate medical attention and special treatment needed	
N/a	

SECTION 5: FIRE FIGHTING MEASURES	
5.1 Extinguishing media	
Suitable:	All systems can be used.
Unsuitable:	None.
5.2 Special hazards arising from the substance or mixture	
Fire incompatibility:	None known
5.3 Special protective actions for fire-fighters:	
Firefighting:	Alert Fire Brigade and tell them location and nature of hazard. Wear full breathing apparatus and self-contained breathing apparatus.
Fire / explosion hazard:	May be combustible at high temperatures.

SECTION 6: ACCIDENTAL RELEASE MEASURES

6.1 Personal precautions, protective equipment and emergency procedures

For information on protective equipment, see section 8.

6.2 Environmental Precautions

Do not allow product to reach drains, sewage systems or any waterways.
 Do not allow to enter sewers/surface or ground water.

6.3 Methods and material for containment and cleaning up

Minor Spills:	Flush/wash residues and small spillages to a suitable container with copious quantities of water
Major Spills:	Clean up all spills immediately. Larger spills should be dammed off, and pumped into a container for waste disposal. Control personal contact with the substance, by using protective equipment such as gloves and eye protection.

SECTION 7: HANDLING AND STORAGE

7.1 Precautions for safe handling

Safe Handling:	Gloves should be worn to administer the product and you should wash hands immediately after administration of the product. When handling, DO NOT eat, drink or smoke. Observe manufacturer's storage and handling recommendations.
Other Information:	Keep out of the reach and sight of children.

7.2 Conditions for safe storage, including any incompatibilities

Suitable Container:	Do not store above 25°C. Store in tightly closed original container. Store in a dry place. Shelf life: 2 years.
Storage incompatibility:	None known.

7.3 Specific end uses

Not available

SECTION 8: EXPOSURE CONTROLS / PERSONAL PROTECTION

8.1 Control parameters

DERIVED NO EFFECT LEVEL - DNEL

Not Available

PREDICTED NO EFFECT LEVEL - PNEC

Not Available

OCCUPATIONAL EXPOSURE LIMITS (OEL)

INGREDIENT DATA:

Not Available

EMERGENCY LIMITS:

Ingredient	Material Name	TEEL-1	TEEL-2	TEEL-3
Not Available				

Ingredient	Original IDLH	Revised IDLH
Not Available		

8.2 Exposure controls

Appropriate engineering controls: The basic types of engineering controls are: Process controls which involve changing the way a job activity or process is done to reduce the particular risk.

Personal protection:



Eye and face protection: Safety glasses with side shields / chemical goggles

Skin protection: See hand protection below

Hands/ feet protection: No special equipment needed when handling small quantities. OTHERWISE: Wear chemical protective gloves

Body protection: Wear appropriate clothing

Other protection: No special equipment needed when handling small quantities

Thermal hazards: Not applicable

Respiratory protection: Not applicable

8.3 Environmental exposure controls
 See Section 12

SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES

9.1 Information on basic physical and chemical properties

Appearance: Prednidale®: White, circular, flat faced tablets with a breakline and PL5 imprinted on one face and CP or DP on the reverse.
 Prednisolone: Solid crystalline powder.

Container: Polypropylene tubs with a low density polyethylene cap (push-fit) with a tamper evident ring, containing 500 or 1000 tablets.

Physical state: Liquid

Odour: Not available

Odour Threshold: Not available

pH (as supplied): Not available

Melting point / freezing point (degrees C): Prednisolone decomposes at 237-239°C

Initial boiling point and boiling range: Not available

Flash Point: Not available

Evaporation rate: Not available

Flammability: Not available

Upper/lower flammability or explosive limits: Not available

Vapour pressure: Not available

Relative Density (at degrees C): Not available

Solubility in water and solvents (mg/l): Prednisolone: very slightly soluble in cold water

Vapour density: Not available

Auto ignition temperature (degrees C): Not available

Decomposition temperature (degrees C): Not available

Viscosity: (degrees C): Not available

Explosive properties: Not available

Oxidising properties: Not available

Partition Coefficient: Not available

Molecular weight: Prednisolone: 360.45 g/mole

Taste: Not available

Surface tension: Not available

Volative component: Not available

Gas group: Not available

pH as a solution: Not available

VOC g/L: Not available

9.2 Other information

Not Available

10: REACTIVITY AND STABILITY

10.1 Reactivity:	See Section 7.
10.2 Chemical stability:	Product is considered stable.
10.3 Possibility of hazardous reactions:	Stable under normal temperatures and conditions.
10.4 Conditions to avoid:	Avoid excess heat and moisture.

10.5 Incompatible materials:	See section 7.
10.6 Hazardous decomposition:	See Section 5.

SECTION 11: TOXICOLOGICAL INFORMATION

Inhalation:	Dust may cause respiratory tract irritation.
Ingestion:	May cause gastrointestinal tract irritation. May also affect behaviour (toxic psychosis), metabolism, and urinary system. The material is readily absorbed from the gastrointestinal tract. Ingestion of a massive single dose is unlikely to cause adverse effects. Prolonged or repeated exposure may cause allergic reaction (possible hypersensitization).
Skin contact:	May cause skin irritation. May be absorbed through the skin. Prolonged or repeated exposure may cause allergic reaction (possible hypersensitisation).
Eye contact:	Dust may cause eye irritation. Prolonged or repeated exposure may cause allergic reaction (possible hypersensitization).
Chronic:	Administration of single high doses are generally tolerated well, but medium to long-term use may provoke reactions. Corticosteroid therapy may lead to increased time in the healing of wounds and to a reduction in the ability of the body to resist infection. Appropriate anti-infective therapy may be required.

Prednidale®:	Acute toxicity	Irritation
	Not Available	Not Available
Prednisolone:	Acute toxicity	Irritation
	Oral (rat) LD ₅₀ : 3857 mg/kg ¹	Not Available

*1. * Value obtained from manufacturer's SDS. Unless otherwise specified, data extracted from RTECS - Register of Toxic Effect of chemical Substances.*

Skin corrosion / irritation:	Not expected to cause skin corrosion or irritation.
Serious eye damage / irritation:	May cause allergic reaction or hypersensitization.
Respiratory or skin sensitization:	May cause allergic reaction or hypersensitization.
Germ cell mutagenicity:	Not thought to produce any mutagenic potential.

SECTION 11: TOXICOLOGICAL INFORMATION

Carcinogenicity:

Not thought to produce any carcinogenic potential.

Reproductive toxicity:

Studies in laboratory animals have shown that administration during early pregnancy may cause foetal abnormalities. Administration during the later stages of pregnancy may cause abortion or early parturition. Insignificant amounts of prednisolone are generally eliminated in the milk of lactating animals, and therefore such use is not contra-indicated.

STOT – single exposure:

Not available

STOT–repeated exposure:

Systemic poisoning may occur.

Aspiration hazard:

Not available

SECTION 12: ECOLOGICAL INFORMATION

12.1 Toxicity

Not Available

12.2 Persistence and degradability

Ingredient	Persistence: Water/soil	Persistence: Air
Prednisolone	HIGH	HIGH

12.3 Bioaccumulative potential

Ingredient	Bioaccumulation
Prednisolone	LOW (LogKOW = 1.62)

12.4 Mobility in Soil

Ingredient	Mobility
Prednisolone	LOW (KOC = 36.36)

12.5 Results of PBT and vPvB assessment
Not Available
12.6 Other adverse effects
Not Available

SECTION 13: DISPOSAL CONSIDERATIONS

13.1 Waste treatment methods	
Product / packaging disposal:	Any unused veterinary medicinal product or waste material derived from such veterinary medicinal products should be disposed of in accordance with national requirements. Legislation addressing waste disposal requirements may differ by country, state and/ or territory. Each user must refer to laws operating in their area. Ensure that the disposal of material is carried out in accordance with Hazardous Substances (Disposal) Regulations 2001.
Waste Treatment Options:	Not Available
Sewage Disposal Options:	Not Available

SECTION 14: TRANSPORT INFORMATION

Labels required:	None
Marine pollutant:	NO
Hazchem:	Not Applicable

Land transport (ADR):		
14.1 UN Number	N/a	
14.2 UN Proper Shipping Name	N/a	
14.3 Transport hazard class(es)	Class	N/a
	Sub risk	N/a
14.4 Packing group	N/a	
14.5 Environmental hazards	N/a	
14.6 Special	Special provisions	N/a

precautions for user	Classification code	N/a
	Hazard Label	N/a
	Special provisions	N/a
	Limited quantity	N/a

14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	N/a	
Air transport (ICAO-IATA / DGR):		
14.1 UN Number	N/a	
14.2 UN Proper Shipping Name	N/a	
14.3 Transport hazard class(es)	ICAO/IATA Class	N/a
	ICAO / IATA Sub risk	N/a
	ERG Code	N/a
14.4 Packing group	N/a	
14.5 Environmental hazards	N/a	
14.6 Special precautions for user	Special provisions	N/a
	Cargo only packing instructions	N/a
	Cargo only maximum qty/pack	N/a
	Passenger and cargo packaging instructions	N/a
	Passenger and cargo maximum qty/pack	N/a
	Passenger and cargo limited quantity packing instructions	N/a
	Passenger and cargo limited maximum qty/pack	N/a



14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	N/a	
Sea transport (IMDG-Code / GGVSee):		
14.1 UN Number	N/a	

14.2 UN Proper Shipping Name	N/a	
14.3 Transport hazard class(es)	IMDG Class	N/a
	IMDG Sub risk	N/a
14.4 Packing group	N/a	
14.5 Environmental hazards	N/a	
14.6 Special precautions for user	EMS Number	N/a
	Special provisions	N/a
	Limited quantities	N/a
14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	N/a	
Inland waterways transport (ADN):		
14.1 UN Number	N/a	
14.2 UN Proper Shipping Name	N/a	
14.3 Transport hazard class(es)	N/a	N/a
14.4 Packing group	N/a	
14.5 Environmental hazard	N/a	

14.6 Special precautions for user	Classification Code	N/a
	Special provisions	N/a
	Limited quantity	N/a
	Equipment required	N/a
	Fire cones number	N/a
14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	N/a	

SECTION 15: REGULATORY INFORMATION

15.1 Safety, health and environmental regulations / legislation specific for the substance or mixture

PREDNISOLONE (50-24-8) IS FOUND ON THE FOLLOWING REGULATORY LISTS:

- European Customs Inventory of Chemical Substances ECICS (English)
- European Union - European Inventory of Existing Commercial Chemical Substances (EINECS) (English)

15.2 Chemical Safety Assessment

ECHA SUMMARY

Ingredient	CAS number	Index Number	ECHA Dossier
Pethidine hydrochloride	50-24-8	Not Available	01-2119560581-40-XXXX

Harmonization (C&L Inventory)	Hazard Class and Category Code(s)	Pictograms Signal Word Code(s)	Hazard Statement Code(s)
1	Acute Tox. 4	GHS07, Wng	H302, H312, H332
2	Repr. 1B, Acute Tox. 4, Repr. 1A, STOT RE 2, Repr. 2, Muta. 2, Carc. 1B, Skin Irrit. 2, Eye Irrit. 2, STOT SE 3	GHS08, Dgr	H302, H312, H332, H360Df, H341, H350, H373, H315, H319, H335, H400
1	Repr. 1A, STOT RE 2	GHS08, Dgr	H360, H373
2	Repr. 1A, STOT RE 2	GHS08, Dgr	H360, H373

Harmonization Code 1 = The most prevalent classification. Harmonization Code 2 = The most severe classification



Australia - AICS	Y
Canada - DSL	Y
Canada - NDSL	N (prednisolone)
China - IECSC	Y
Europe - EINEC / ELINCS / NLP	Y
Japan - ENCS	N (prednisolone)
Korea - KECI	Y
New Zealand - NZIoC	Y
Philippines - PICCS	Y
USA - TSCA	Y
Legend:	<i>Y = All ingredients are on the inventory N = Not determined or one or more ingredients are not on the inventory and are not exempt from listing(see specific ingredients in brackets)</i>

SECTION 16: OTHER INFORMATION

The SDS is written in accordance to guidelines specified by REACH, GHS and ECHA.

For detailed advice on Personal Protective Equipment, refer to the following EU CEN Standards:

EN 166 Personal eye-protection
EN 340 Protective clothing
EN 374 Protective gloves against chemicals and micro-organisms
EN 13832 Footwear protecting against chemicals
EN 133 Respiratory protective devices

Definitions and abbreviations

PC—TWA: Permissible Concentration-Time Weighted Average
PC—STEL: Permissible Concentration-Short Term Exposure Limit
STEL: Short Term Exposure Limit
TEEL: Temporary Emergency Exposure Limit
IDLH: Immediately Dangerous to Life or Health Concentrations

The information provided in this Safety Data Sheet has been compiled by Dechra Ltd using a number of different sources, and is correct to the best of its knowledge, information and belief as at the date of its publication. However, Dechra Ltd makes no warranties, express or implied, in relation to the information set out in this Safety Data Sheet, including, without limitation, as to its accuracy or completeness.

The information provided is not a quality specification, and is prepared by way of guidance as to the safe handling, use, processing, storage, transportation, disposal and release of the relevant products referred to. The user is responsible for determining whether or not the product is fit for any particular purpose and/or suitable for the user's proposed method of use and application.

Copyright, 2017, Dechra Ltd. All rights reserved.

Copying and/or downloading of this information for the purpose of properly utilizing Dechra Ltd products is permitted provided that: (1) the information is copied in full with no changes unless prior written agreement is obtained from Dechra Ltd, and (2) neither the copy nor the original is resold or otherwise distributed for the purposes of making a profit thereon.